MSD in the UK
Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co., Inc., is a leading global healthcare company headquartered in Great Britain. Established in 1891, MSD has made significant strides in the pharmaceutical industry, focusing on innovative medicines, vaccines, and animal health products. With major operational regions across Europe, the Middle East, and Africa, MSD is committed to improving health outcomes through research and development. The company is renowned for its core products, including groundbreaking treatments in oncology, infectious diseases, and vaccines, which are distinguished by their efficacy and safety profiles. MSD's dedication to scientific advancement has positioned it as a key player in the UK market, with notable achievements in drug development and a strong commitment to public health initiatives.
DitchCarbon Score
How does MSD in the UK's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
MSD in the UK's score of 3 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
MSD in the UK's reported carbon emissions
In 2021, MSD in the UK reported total carbon emissions of approximately 31,190,000 kg CO2e, a significant reduction from about 41,520,000 kg CO2e in 2019. This decline reflects a commitment to reducing their carbon footprint across all scopes of emissions. In 2021, their emissions breakdown included approximately 4,330,000 kg CO2e from Scope 1, which covers direct emissions from owned or controlled sources, and about 1,390,000 kg CO2e from Scope 2, representing indirect emissions from the generation of purchased electricity. The majority of their emissions, approximately 25,470,000 kg CO2e, fell under Scope 3, which includes all other indirect emissions. Notably, business travel accounted for about 4,740,000 kg CO2e, while upstream transportation and distribution contributed approximately 11,020,000 kg CO2e. Despite these reductions, MSD has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. Their ongoing efforts to decrease emissions demonstrate a proactive approach to addressing climate change within the pharmaceutical industry in the UK.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
MSD in the UK is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
